- Summary
- Table Of Content
- Methodology
Etanercept Market Introduction :
Consegic Business Intelligence analyzes that the Etanercept market size is growing with a CAGR of 3.2% during the forecast period (2023-2031). The market accounted for USD 16,032.50 million in 2022 and USD 16,454.45 million in 2023, and the market is projected to be valued at USD 21,184.88 Million by 2031.
Etanercept Market Definition & Overview :
Etanercept is a biologic medication used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, plaque psoriasis, and Crohn's disease. It is a tumor necrosis factor (TNF)-alpha inhibitor, which means that it blocks the activity of TNF-alpha, a protein that plays a key role in inflammation.
Based on the analysis, the medication is administered by injection under the skin (subcutaneously). It is typically given once a week, but the frequency of injections may vary depending on the condition being treated and the patient's response to treatment. Overall, the medication is a safe and effective medication for many people with autoimmune diseases. It can help to improve quality of life and slow the progression of disease.
Etanercept Market Insights :
Etanercept Market Dynamics - (DRO) :
Key Drivers :
The increasing prevalence of autoimmune diseases is driving the market
Etanercept is a biologic medication that is used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, plaque psoriasis, and Crohn's disease. Autoimmune disease is a group of conditions in which the body's immune system attacks healthy tissues and organs. There are over 100 different types of autoimmune diseases, and they can affect any part of the body. The medication works by blocking the activity of tumor necrosis factor (TNF)-alpha, a protein that plays a key role in inflammation. Significant development in autoimmune diseases is driving the market growth. For instance, according to the report by Global Autoimmune Institute in August 2022, Autoimmune diseases are increasing internationally, and the global cases of autoimmune cases are rising by 3–9% a year. In the United States, the number of people with at least one autoimmune disease is closer to 8%. Thus, the growing prevalence of autoimmune disease is driving the demand of this medication for the treatment of such types of diseases.
Growing government initiatives to increase awareness about arthritis
Etanercept has a wide range of applications in treating severe autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis. It binds with tumor necrosis factor alpha receptor and is used under the brand name Embrel in the market. As per the analysis, with the rising cases of various arthritis across the regions, government authorities initiate awareness campaigns and programs to educate the population about the severities caused by these disorders. For instance, as of 13th June 2023, CDC's Arthritis Management and Wellbeing Program has initiated evidence-based public awareness campaigns to promote physical activity and self-management education as useful approaches to managing arthritis. This campaign aims to promote physical activity to Spanish-speaking Americans with arthritis between the ages of 45–64, with an annual income of USD 35,000 or less. With the growing knowledge and awareness among people about applications of this medication in arthritis, the market is anticipated to grow at a substantiate rate. Thus, the increasing awareness about arthritis is propelling the market trends
Key Restraints :
Side effects associated with utilization of etanercept
Etanercept is a highly effective biologic drug used to treat a variety of autoimmune diseases. However, it is associated with several side effects, some of which can be serious. These side effects can deter patients from taking this medication or cause them to stop taking it altogether, which can restrain the market. As per the analysis, the injections decrease the tolerance level of the individual to take more injections and increase the susceptibility to get infected easily by several viral, bacterial, and fungal infections that spread throughout the entire body. Such infections, if not treated properly, may lead to fatalities. Other severe common conditions developed through injections include problems like headache, nausea, and weakness in the body. Hence, it is firmly advised to take injections containing this medication in hospitals to avoid any unfortunate circumstances. Even a little fluctuation in the amount of dosage leads to unwanted side effects and presents a severe threat to the patient. Thus, it is evident that the severe side effects associated with the use of this medication create valid fright among the users and motivate them to look for other alternatives. Consequently, the market experiences a slowdown in operational activities, and the trends of the market is impeded. As a result, the toxicity of this medication to the environment and human health is hampering market.
Future Opportunities :
Increasing development of biosimilar etanercept products
The increasing development of biosimilars is creating lucrative opportunities and trends in the upcoming years. Biosimilars are highly similar versions of biologic drugs that have been approved for marketing. They are typically less expensive than the original biologic drugs, and they are expected to play an increasingly important role in the etanercept market in the forecast years. As per the analysis, biosimilar products are expected to increase access to this treatment for patients in developed and emerging markets. Furthermore, biosimilars are expected to drive down the cost of this treatment. Increasing launches of new biosimilar products are expected to drive market trends.
For instance, in August 2020, Lupin and Mylan launched Nepexto biosimilar etanercept, in the German market. Nepexto is a biosimilar to Enbrel, a leading treatment for autoimmune diseases. Nepexto is approved for all therapeutic indications of Enbrel, including moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondylarthritis, and plaque psoriasis. The launch of Nepexto in Germany is expected to increase access to affordable and effective treatment for patients with autoimmune diseases. Overall, the increasing development of biosimilar versions of this products is expected to positively drive the global etanercept market trend over the forecast period.
Etanercept Market Report Insights :
| Report Attributes | Report Details |
| Study Timeline | 2017-2031 |
| Market Size in 2031 | USD 21,184.88 Million |
| CAGR (2023-2031) | 3.2% |
| By Drug Type | Enbrel, Benepali, and Others |
| By Form | Liquid Solution and Powder for Injections |
| By Application | Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Players | Pfizer Limited., Amgen Inc., Samsung Bioepis, Lupin, Novartis, Clover Biopharmaceuticals, and AbbVie Inc. |
Etanercept Market Segmental Analysis :
Based on the Drug Type :
The drug type of segmentation is categorized into enbrel, benepali, and others. In 2022, benepali accounted for the highest market share in the etanercept market, and it is also expected to hold the highest CAGR over the forecast period. Benepali is a biosimilar version of this medication. Biosimilars are highly similar versions of biologic drugs that have been approved for marketing. As per the analysis, they are typically less expensive than the original biologic drugs, and they are expected to play an increasingly important role in the etanercept market and creative lucrative trends.
Benepali is more affordable than the original etanercept product, Enbrel. This makes it a more attractive option for patients and payers, especially in emerging markets where the cost of healthcare is a major concern. As per the analysis, significant development in healthcare expenditure is the primary factor driving the demand for benepali across the globe. For instance, according to the report by General Government Expenditure (GGE) in April 2023, the share of health sector spending has steadily increased from 3.94% to 5.02% between 2014-15 and 2019-2020. Thus, the increasing spending on healthcare and the high benefits of benepali over Enbrel is driving the segment expansion across the globe over the forecast period.
Based on the Form :
The form segment is categorized into liquid solution and powder for injections. In 2022, the powder for injections segment accounted for the highest market revenue in the etanercept market. Powder for injection form of this medication is more convenient to administer than the liquid solution form. It can be self-injected at home, which eliminates the need for frequent visits to the doctor's office. Furthermore, powder for injection form of the medication is more cost-effective than the liquid solution form. This is because the powder form can be stored at room temperature, while the liquid form needs to be refrigerated. This can save patients and healthcare providers money on storage costs. Thus, the powder-for-injection form of this medication is a highly used and in-demand drug due to its ease of administration, cost-effectiveness, flexibility, versatility, and the increasing prevalence of autoimmune diseases.
Based on the Application :
The application segment is categorized into juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and others. In 2022, the rheumatoid arthritis segment accounted for the highest market share in the application segment, and it is also expected to hold the highest CAGR over the forecast period. It is a highly effective treatment for the treatment of rheumatoid arthritis. It is a biological drug that works by blocking the activity of tumor necrosis factor (TNF)-alpha, a protein that plays a key role in inflammation. The medication also helps to reduce inflammation, pain, and swelling in patients with RA, and it can also slow the progression of the disease. The growing prevalence of rheumatoid arthritis is further driving the application growth across the globe. For instance, according to the report by the World Health Organization in June 2023, in 2019, 18 million people worldwide were living with rheumatoid arthritis, 13 million people with rheumatoid arthritis experience severity levels (moderate or severe) that could benefit from rehabilitation. Thus, the growing demand for this medication for the treatment of rheumatoid arthritis is due to its high efficacy, safety, and convenience thus driving the etanercept market growth.
Based on the Region :
The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In 2022, North America accounted for the highest etanercept market share at 38.30% valued at USD 6,140.45 Million in 2022 and USD 6,310.28 Million in 2023, it is expected to reach USD 8,139.23 Million in 2031. In North America, the U.S. accounted for the highest market share of 62.70% in the base year 2022. Based on the etanercept market analysis, the high prevalence of autoimmune diseases across the region is driving the market growth across North America. For instance, the National Institutes for Health (NIH) estimates that autoimmune diseases affect between 5% and 8% of the U.S. population. This is the third most common cause of chronic illness in the United States. Thus, the growing prevalence of autoimmune disease in the North America region is driving demand for this medication trends, which is used in a variety of autoimmune disease treatments.
Furthermore, the Asia Pacific region is expected to witness significant growth over the forecast period, growing at a CAGR of 3.9% during 2023-2031. The significant growth in the pharmaceutical and healthcare industry as well as the growing geriatric population across the region is increasing etanercept market demand. For instance, according to a report by Asia Development Bank, by 2050, one in four people in Asia and the Pacific will be over 60 years old. The population of older persons (aged over 60) in the region will triple between 2010 and 2050, reaching close to 1.3 billion people. Thus, the significant growth in geriatric is expected to create etanercept market opportunities and trends over the forecast period.
Top Key Players & Market Share Insights :
The global etanercept market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The etanercept industry is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market revenue through mergers, acquisitions, and partnerships. The key players in the market include-
- Pfizer Limited
- Amgen Inc.
- Novartis
- AbbVie Inc.
- Samsung Bioepis
- AbbVie Inc
- Lupina
Recent Industry Developments :
- In March 2022, Pfizer launches ENBREL SmartClic, a new self-injecting device for ENBREL patients in Australia, with a companion smartphone app. ENBREL is a tumor necrosis factor (TNF) inhibitor indicated for the treatment of diseases such as Rheumatoid Arthritis (RA), which affects close to half a million Australians and is expected to increase.
- In March 2021, Samsung Bioepis Co., Ltd. announced the expansion of its global footprint to Australia with the launch of HADLIMA i (adalimumab), a biosimilar referencing HUMIRA ii(adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.
Key Questions Answered in the Report
What was the market size of the etanercept market in 2022? +
In 2022, the market size of etanercept was USD 16,032.50 million.
What will be the potential market valuation for the etanercept industry by 2031? +
In 2031, the market size of Etanercept will be expected to reach USD 21,184.88 million.
What are the key factors driving the growth of the etanercept market? +
Increasing prevalence of autoimmune diseases across the globe is fueling market growth at the global level.
What is the dominant segment in the etanercept market for the application? +
In 2022, the rheumatoid arthritis segment accounted for the highest market share of 32.50% in the overall etanercept market.
Based on current market trends and future predictions, which geographical region is the dominating region in the etanercept market? +
North America accounted for the highest market share in the overall market.
